GENE ONLINE|News &
Opinion
Blog

2018-07-11| Trials & Approvals

CFDA processes priority review of BGI’s BRCA1/2 gene testing kit

by GeneOnline
Share To

The BRCA1/2 gene mutation detection kit by the BGI Wuhan Ltd., a subsidiary of the Beijing Genomics Institute (BGI), received the priority reviewing notice from the Centre of Medical Device Evaluation, China Food and Drug Administration (CFDA) [1]. This BRCA1/2 gene testing kit is the first genetic test to be listed on the innovative medical device priority reviewing process.

By Joanne Shih

This BRCA1/2 gene mutation detection kit is performed with BGI’s in-house high-throughput sequencer and with combinatorial probe anchor synthesis (cPAS)-based sequencing method. This kit is designed for detecting germline variant of the exon and adjacent intron regions of BRCA1 and BRCA2 genes in patients with clinically diagnosed ovarian cancer and breast cancer.

The existence of BRCA1 and BRCA2 mutations is highly related to the efficacy of poly (ADP-ribose) polymerase (PARP) inhibitors when treating cancer. Therefore, being able to quantify the gene mutations in patients with BRCA-related cancers will allow clinicians to make more accurate treatment decision and advance the outcome of targeted therapy that uses PARP inhibitors.

If this BGI’s gene testing kit receive further approval from CFDA, it will be the first gene testing kit guiding the use of PARP inhibitors and may be beneficial to a large number of cancer patients.

Reference

  1. Centre of Medical Device Evaluation.CFDA: http://www.cmde.org.cn/CL0050/7586.html
  2. Okuma HS, Yonemori K. BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer. DOI. 10.1007/978-981-10-6020-5_13
  3. https://xueqiu.com/1912517390/110207640

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Merck’s KEYNOTE-522 Success; BMS Licenses PRX019, Prothena Gets $80M
2024-06-19
AACR Showcases Breakthroughs in Novel Breast Cancer Diagnosis and Treatment Strategies
2024-04-09
BeiGene to Expand Oncology Pipeline Through ENSEM Therapeutics Partnership
2023-11-23
LATEST
Accelerated Bio and Pluristyx Generate Clinical-Grade Induced Pluripotent Stem Cells from Reprogrammed Human Trophoblast Stem Cells
2024-07-12
Novo Nordisk and PT Bio Farma Agree to Enhance Insulin Production for Diabetes Patients in Indonesia
2024-07-12
Alzheimer’s Drug LEQEMBI Approved for Treatment in Hong Kong
2024-07-12
Foreseen Biotech Strikes $1.03B Deal with Ipsen for First-in-Class ADC
2024-07-12
Synthetic Biology’s Innovator Dr. John Cumbers – Addressing Inefficiencies in Biopharma and Economic Sustainability
2024-07-11
Delivering Affordable Biologic Medicines Worldwide: An Interview with Tanvex Chairman and CEO, Henry Chen
2024-07-11
Roche Secures CE Mark for AI-Powered Glucose Monitoring Solution, Enhancing Diabetes Care with Predictive Insights
2024-07-11
EVENT
Scroll to Top